"tapp" Into The Truth

The House Energy and Commerce Committee will hold a healthcare affordability hearing on Thursday, February 12, focused on the pharmaceutical supply chain, even as drugmakers raised prices on nearly 1,000 prescription drugs this January, and pharmaceutical CEOs are not expected to testify. Why is Big Pharma's "patient-last" playbook continuing despite the recent White House deals? What do lawmakers risk overlooking if drug manufacturers are not at the witness table? As lawmakers revisit the topic of affordability, it's critical they remember that lowering Big Pharma's drug prices and enacting a Most-Favored-Nation drug pricing policy are top healthcare policy priorities for the administration – and for Americans in general. J.D. Hayworth, a former member of the House Ways and Means Committee and now spokesperson for the Pharmaceutical Reform Alliance, joins me to share his insights.Tom Homan has brought a new spirit of cooperation and "work smarter, not harder" to immigration law enforcement in Minnesota. The